Увійти

Готові списки джерел за темами / Anticancer drugs / Статті в журналах

Статті в журналах з теми "Anticancer drugs"

Щоб переглянути інші типи публікацій з цієї теми, перейдіть за посиланням: Anticancer drugs.

Автор: Grafiati

Опубліковано: 4 червня 2021

Оновлено: 6 вересня 2023

Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями

Оберіть тип джерела:

Ознайомтеся з топ-50 статей у журналах для дослідження на тему "Anticancer drugs".

Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.

Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.

Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.

1

D, Subba Reddy, Prasanthi G, Amruth Raj S, Hari Krishna T, Sowjanya K, and Shantha Kumari K. "EVALUATION OF ANTICANCER GENERIC DRUGS AND BRANDED DRUGS." Indian Research Journal of Pharmacy and Science 5, no. 1 (March 2018): 1378–91. http://dx.doi.org/10.21276/irjps.2018.5.1.16.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

2

Reese, David M. "Anticancer drugs." Nature 378, no. 6557 (December 1995): 532. http://dx.doi.org/10.1038/378532c0.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

3

Kutty, Dr A. V. M. "Usefulness of Phytochemicals as Anticancer Drugs." JOURNAL OF CLINICAL AND BIOMEDICAL SCIENCES 16, no. 1 (March 19, 2019): 1–2. http://dx.doi.org/10.58739/jcbs/v09i1.7.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Cancer is a state of uncontrolled proliferation and dedifferentiation of cells in any tissues or organs of the body. The incidence of cancer is rising alarmingly and is one of the leading causes of morbidity and mortality globally. Normal cell division is precisely a planned biological process controlled by regulatory genes and specific metabolic pathways. Exposure of normally functioning cells to carcinogens leads to mutations in the genes causing loss of control of cell division and transform into cancerous. Over a period of time, these cancer cells acquire more mutations; invade to adjoining tissues, escape the process of apoptosis and the cells become eternal. Breakaway parts of the cancer tissues / cells travel through the lymphatic and blood vessels and get deposited in other tissues / organs leading to metastasis, the spread of cancer.

4

Atkins, Joshua H., and Leland J. Gershell. "Selective anticancer drugs." Nature Reviews Drug Discovery 1, no. 7 (July 2002): 491–92. http://dx.doi.org/10.1038/nrd842.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

5

Atkins, Joshua H., and Leland J. Gershell. "Selective anticancer drugs." Nature Reviews Cancer 2, no. 9 (September 2002): 645–46. http://dx.doi.org/10.1038/nrc900.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

6

Bibby, M. C. "Combretastatin anticancer drugs." Drugs of the Future 27, no. 5 (2002): 475. http://dx.doi.org/10.1358/dof.2002.027.05.668645.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

7

Meegan, Mary J., and Niamh M. O’Boyle. "Special Issue “Anticancer Drugs”." Pharmaceuticals 12, no. 3 (September 16, 2019): 134. http://dx.doi.org/10.3390/ph12030134.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

The focus of this Special Issue of Pharmaceuticals is on the design, synthesis, and molecular mechanism of action of novel antitumor, drugs with a special emphasis on the relationship between the chemical structure and the biological activity of the molecules. This Special Issue also provides an understanding of the biologic and genotypic context in which targets are selected for oncology drug discovery, thus providing a rationalization for the biological activity of these drugs and guiding the design of more effective agents. In this Special Issue of Pharmaceuticals dedicated to anticancer drugs, we present a selection of preclinical research papers including both traditional chemotherapeutic agents and newer more targeted therapies and biological agents. We have included articles that report the design of small molecules with promising anticancer activity as tubulin inhibitors, vascular targeting agents, and topoisomerase targeting agents, alongside a comprehensive review of clinically successful antibody-drug conjugates used in cancer treatment.

8

Ciarimboli, Giuliano. "Anticancer Platinum Drugs Update." Biomolecules 11, no. 11 (November 4, 2021): 1637. http://dx.doi.org/10.3390/biom11111637.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

9

Zhang, Jason Y. "Apoptosis-based anticancer drugs." Nature Reviews Drug Discovery 1, no. 2 (February 2002): 101–2. http://dx.doi.org/10.1038/nrd742.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

10

Blagosklonny, Mikhail V. "Teratogens as Anticancer Drugs." Cell Cycle 4, no. 11 (August 22, 2005): 1518–21. http://dx.doi.org/10.4161/cc.4.11.2208.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

11

KOPEČEK, JINDŘICH. "Targetable Polymeric Anticancer Drugs." Annals of the New York Academy of Sciences 618, no. 1 Temporal Cont (February 1991): 335–44. http://dx.doi.org/10.1111/j.1749-6632.1991.tb27253.x.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

12

Mundy, Gregory R., and Toshiyuki Yoneda. "Bisphosphonates as Anticancer Drugs." New England Journal of Medicine 339, no. 6 (August 6, 1998): 398–400. http://dx.doi.org/10.1056/nejm199808063390609.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

13

Miyamoto, Shingo, Manabu Yamada, Yasuyo Kasai, Akito Miyauchi, and Kazumichi Andoh. "Anticancer drugs during pregnancy." Japanese Journal of Clinical Oncology 46, no. 9 (June 9, 2016): 795–804. http://dx.doi.org/10.1093/jjco/hyw073.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

14

Xing, Z., D. Li, L. Yang, Y. Xi, and X. Su. "MicroRNAs and anticancer drugs." Acta Biochimica et Biophysica Sinica 46, no. 3 (February 3, 2014): 233–39. http://dx.doi.org/10.1093/abbs/gmu003.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

15

Wallis, Denise, James Claffey, Brendan Gleeson, Megan Hogan, Helge Müller-Bunz, and Matthias Tacke. "Novel zirconocene anticancer drugs?" Journal of Organometallic Chemistry 694, no. 6 (March 2009): 828–33. http://dx.doi.org/10.1016/j.jorganchem.2008.08.020.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

16

Bradley, David. "Self-assembling anticancer drugs." Materials Today 41 (December 2020): 3. http://dx.doi.org/10.1016/j.mattod.2020.10.015.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

17

Russell, Stephen J., and Kah-Whye Peng. "Viruses as anticancer drugs." Trends in Pharmacological Sciences 28, no. 7 (July 2007): 326–33. http://dx.doi.org/10.1016/j.tips.2007.05.005.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

18

Kerwin, Sean. "Toward Bioengineering Anticancer Drugs." Chemistry & Biology 9, no. 9 (September 2002): 956–58. http://dx.doi.org/10.1016/s1074-5521(02)00222-3.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

19

Rohr, Jürgen. "Cryptophycin Anticancer Drugs Revisited." ACS Chemical Biology 1, no. 12 (December 2006): 747–50. http://dx.doi.org/10.1021/cb6004678.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

20

Denny, William A. "Hypoxia-activated anticancer drugs." Expert Opinion on Therapeutic Patents 15, no. 6 (June 2005): 635–46. http://dx.doi.org/10.1517/13543776.15.6.635.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

21

Bordon, Yvonne. "Anticancer drugs copy bugs." Nature Reviews Cancer 14, no. 12 (November 24, 2014): 767. http://dx.doi.org/10.1038/nrc3866.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

22

Van der Veldt, Astrid A. M., Adriaan A. Lammertsma, and Egbert F. Smit. "Scheduling of anticancer drugs." Cell Cycle 11, no. 23 (December 2012): 4339–43. http://dx.doi.org/10.4161/cc.22187.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

23

Mundy, Gregory R. "Bisphosphonates as anticancer drugs." Expert Opinion on Investigational Drugs 8, no. 12 (December 1999): 2009–15. http://dx.doi.org/10.1517/13543784.8.12.2009.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

24

Bordon, Yvonne. "Anticancer drugs need bugs." Nature Reviews Immunology 14, no. 1 (December 13, 2013): 1. http://dx.doi.org/10.1038/nri3591.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

25

Bordon, Yvonne. "Anticancer drugs copy bugs." Nature Reviews Immunology 14, no. 12 (November 14, 2014): 776–77. http://dx.doi.org/10.1038/nri3775.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

26

Jefford, Michael, Linda Mileshkin, Penelope Schofield, Emilia Agalianos, Jacqui Thomson, and John Zalcberg. "Discussing Expensive Anticancer Drugs." Journal of Clinical Oncology 27, no. 3 (January 20, 2009): 476–77. http://dx.doi.org/10.1200/jco.2008.20.1780.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

27

Schwartsmann, G. "Anticancer drugs from nature." Medical and Pediatric Oncology 37, no. 1 (2001): 79–80. http://dx.doi.org/10.1002/mpo.1173.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

28

Janus, Nicolas. "Gastrointestinal Disorders and Toxicities Induced By Anticancer Drugs. Another Risk Factor of Bleeding in Cancer-Associated Thrombosis." Blood 136, Supplement 1 (November 5, 2020): 36. http://dx.doi.org/10.1182/blood-2020-141814.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Introduction Anticancer treatments has been changing since decades, evolving from chemotherapy (platinum salts) to recent check-point inhibitors. Nausea, vomiting and diarrhoea are common adverse events of anticancer drugs, despites the fact that some supportive care drugs can manage these adverse events. Gastro-intestinal (GI) disorders/toxicities are also important. Such as gastric/duodenal ulcer, gastritis, stomatitis, colitis, esophagitis... Cancer-associated-thrombosis (CAT) patients were also reported to be exposed to such GI disorders/toxicities and several publications recommended to consider these GI disorders/toxicities when choosing an anticoagulant in CAT (Carrier M. Curr Oncol 2018; Moik F. ESMO Open 2020). However, little is known about the nature of the anticancer drugs that CAT patients are receiving. The aim of this work was to check all the anticancer's SmPCs (Summary of Product Characteristics) on the EMA website for GI disorders. Methods All SmPCs of anticancer drugs indicated for lung cancer were checked on the EMA website. All adverse events regarding GI disorders/toxicities were collected. The frequency of adverse events used was the following: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1000); very rare (< 1/10,000). However, it was decided to mainly focus on very common and common ones. Old anticancer drugs SmPCs (platinium salts...) were checked on electronic medicines compendium (medicines.org.uk), because these old SmPCs are not always available on the EMA website. Generics, biosimilars and drugs without a licence were excluded. Results Twenty-eight anticancer drugs were identified with a mix of traditional chemotherapies (platinum salts...), tyrosine kinase inhibitors (nib) and monoclonal antibodies (mab). Among these 28 anticancer drugs, 26 had at least one very common/common GI disorders/toxicities. Obviously, vomiting (82.1%) and diarrhoea (89.3%) are very well-known, but it was interesting to see that many anticancer drugs were associated with other very common/common GI toxicities such as stomatitis (71.4%) and colitis (10.7%). Additionally, several drugs (35.7%) were exposing to GI bleeding and/or GI perforation but these last adverse events were less common. Unfortunately, the SmPCs did not include data about the GI profile of the patients during the trials. Conclusion Monreal M et al reported in 1991 that acute gastroduodenal lesion was found in 21% of patients with venous thromboembolism, but there are no dedicated study about the incidence of GI disorders in CAT patients. This work reported that GI disorders/toxicities were common in anticancer drug's SmPCs. Consequently, it is important to be aware of this before initiating an anticoagulant treatment. However, this work had limitations. Indeed, these adverse events were reported in the SmPCs, based mainly on cancer trials and not on CAT trials. Furthermore, clinical trials and SmPCs may not always reflect the real clinical setting. Finally, lung cancer patients are usually receiving anticancer regimens that include several anticancer drugs, so the potential impact of GI disorders/toxicities from 2 or 3 anticancer drugs on a single patients could be greater. Nevertheless, it sounds reasonable to check for GI disorders/toxicities risks in order to initiate an adequate anticoagulant treatment in CAT patients and during follow-up. Disclosures Janus: Guerbet:Research Funding;B-Braun:Honoraria;LEO Pharma A/S:Current Employment, Honoraria;Fresenius Medical Care:Honoraria;Amgen:Honoraria, Research Funding;TEVA:Research Funding;Daichii-Sankyo:Honoraria, Research Funding;Roche:Honoraria, Research Funding;Vifor Pharma:Honoraria, Research Funding;Gilead:Honoraria, Research Funding;Novartis:Honoraria;Pierre Fabre Oncology:Research Funding;Bayer:Honoraria, Research Funding;Pfizer:Consultancy, Honoraria;IPSEN:Honoraria.

29

Li, Dong Hong, Jun Lin Diao, Ke Gui Yu, and Cheng He Zhou. "Synthesis and anticancer activities of porphyrin induced anticancer drugs." Chinese Chemical Letters 18, no. 11 (November 2007): 1331–34. http://dx.doi.org/10.1016/j.cclet.2007.09.012.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

30

&NA;. "Anticancer drugs from the sea." Inpharma Weekly &NA;, no. 1417 (December 2003): 4. http://dx.doi.org/10.2165/00128413-200314170-00007.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

31

Evans, William E., and Mary V. Relling. "Clinical Pharmacokinetics-Pharmacodynamicsof Anticancer Drugs." Clinical Pharmacokinetics 16, no. 6 (June 1989): 327–36. http://dx.doi.org/10.2165/00003088-198916060-00001.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

32

Carcone, Bernard, and Dionyssis Pongas. "Cardiovascular toxicity of anticancer drugs." Sang thrombose vaisseaux 26, no. 4 (July 2014): 188–96. http://dx.doi.org/10.1684/stv.2014.0849.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

33

Amelio, Ivano, Andrey Lisitsa, Richard Knight, Gerry Melino, and Alexey Antonov. "Polypharmacology of Approved Anticancer Drugs." Current Drug Targets 18, no. 5 (February 24, 2017): 534–43. http://dx.doi.org/10.2174/1389450117666160301095233.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

34

Jeanny B. Aragon-Ching, Haiqing Li, Erin R. Gardner, and William D. Figg. "Thalidomide Analogues as Anticancer Drugs." Recent Patents on Anti-Cancer Drug Discovery 2, no. 2 (June 1, 2007): 167–74. http://dx.doi.org/10.2174/157489207780832478.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

35

Meegan, Mary J., and Niamh M. O’Boyle. "Special Issue “Anticancer Drugs 2021”." Pharmaceuticals 15, no. 4 (April 14, 2022): 479. http://dx.doi.org/10.3390/ph15040479.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

36

Benjamin Garbutcheon-Singh, K., Maxine P. Grant, Benjamin W. Harper, Anwen M. Krause-Heuer, Madhura Manohar, Nikita Orkey, and Janice R. Aldrich-Wright. "Transition Metal Based Anticancer Drugs." Current Topics in Medicinal Chemistry 11, no. 5 (March 1, 2011): 521–42. http://dx.doi.org/10.2174/156802611794785226.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

37

Fujita, Ken-ichi. "Cytochrome P450 and Anticancer Drugs." Current Drug Metabolism 7, no. 1 (January 1, 2006): 23–37. http://dx.doi.org/10.2174/138920006774832587.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

38

Wallace, H. M., and A. V. Fraser. "Polyamine analogues as anticancer drugs." Biochemical Society Transactions 31, no. 2 (April 1, 2003): 393–96. http://dx.doi.org/10.1042/bst0310393.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

Анотація:

Just over 30 years ago, the late Diane Russell published the first in a series of papers linking polyamines and cancer. These early studies led to a flurry of research activity in the polyamine field that continues to this day attempting to identify a role for the polyamines in cancer development, treatment and/or prevention. The recognition that polyamines are critical for the growth of cancer cells, and consequently the identification of their metabolic pathways as a target for therapeutic intervention, led to the development of a number of useful inhibitors of polyamine biosynthesis. Arguably the most significant addition to the polyamine field in the last 30 years was the synthesis of α-difluoromethylornithine (DFMO), which is being tested currently as a cancer chemopreventative agent in man and is used also as a highly effective trypanocidal agent. Although an extremely useful tool experimentally, DFMO has been disappointing in clinical trials with little therapeutic efficacy. Despite this setback, the polyamine pathway is still considered a viable target for chemotherapeutic intervention. This has led to the development of the polyamine analogues as multifunctional inhibitors that will produce inhibition of tumour cell growth, polyamine depletion and optimum therapeutic efficacy.

39

Hyodo, Kenji, Eiichi Yamamoto, Takuya Suzuki, Hiroshi Kikuchi, Makoto Asano, and Hiroshi Ishihara. "Development of Liposomal Anticancer Drugs." Biological and Pharmaceutical Bulletin 36, no. 5 (2013): 703–7. http://dx.doi.org/10.1248/bpb.b12-01106.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

40

Powis, Garth, Miles P. Hacker, and Graziano C. Carlon. "The Toxicity of Anticancer Drugs." Critical Care Medicine 21, no. 7 (July 1993): 1101. http://dx.doi.org/10.1097/00003246-199307000-00034.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

41

Baumann, F., and R. Preiss. "Cyclophosphamide and related anticancer drugs." Journal of Chromatography B: Biomedical Sciences and Applications 764, no. 1-2 (November 2001): 173–92. http://dx.doi.org/10.1016/s0378-4347(01)00279-1.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

42

Tjaden, U. R., and E. A. De Bruijn. "Chromatographic analysis of anticancer drugs." Journal of Chromatography B: Biomedical Sciences and Applications 531 (October 1990): 235–94. http://dx.doi.org/10.1016/s0378-4347(00)82286-0.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

43

Sapra, P., and T. M. Allen. "Ligand-targeted liposomal anticancer drugs." Progress in Lipid Research 42, no. 5 (September 2003): 439–62. http://dx.doi.org/10.1016/s0163-7827(03)00032-8.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

44

Tanigawara, Y. "Pharmaco-Metabolomics for Anticancer Drugs." Annals of Oncology 23 (October 2012): xi55. http://dx.doi.org/10.1016/s0923-7534(20)32076-7.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

45

Yoshioka, T. "Drugs Interaction of Anticancer Agents." Annals of Oncology 23 (October 2012): xi65. http://dx.doi.org/10.1016/s0923-7534(20)32111-6.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

46

Muers, Mary. "Transgenerational effects of anticancer drugs." Nature Reviews Genetics 13, no. 3 (February 14, 2012): 148. http://dx.doi.org/10.1038/nrg3190.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

47

Gosland, Michael P., and Bert L. Lum. "The Anticancer Drugs, 2nd Edition." Annals of Pharmacotherapy 29, no. 3 (March 1995): 320. http://dx.doi.org/10.1177/106002809502900321.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

48

Meyer, G. "Pulmonary Toxicity of Anticancer Drugs." Annals of Oncology 25 (September 2014): iv33. http://dx.doi.org/10.1093/annonc/mdu310.2.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

49

Imran, Muhammad, Wagma Ayub, Ian S. Butler, and Zia-ur-Rehman. "Photoactivated platinum-based anticancer drugs." Coordination Chemistry Reviews 376 (December 2018): 405–29. http://dx.doi.org/10.1016/j.ccr.2018.08.009.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.

50

SALVIK, MILAN, JUN WU, and CHRISTOPHER RILEY. "Salivary Excretion of Anticancer Drugs." Annals of the New York Academy of Sciences 694, no. 1 Saliva as a D (September 1993): 319–21. http://dx.doi.org/10.1111/j.1749-6632.1993.tb18377.x.

Повний текст джерела

Стилі APA, Harvard, Vancouver, ISO та ін.